We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
- Authors
Brown, Jacob T.; Bishop, Jeffrey R.; Sangkuhl, Katrin; Nurmi, Erika L.; Mueller, Daniel J.; Dinh, Jean C.; Gaedigk, Andrea; Klein, Teri E.; Caudle, Kelly E.; McCracken, James T.; Leon, Jose; Leeder, J. Steven
- Abstract
Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
- Subjects
CYTOCHROME P-450; ATOMOXETINE; PHARMACOGENOMICS; GENOTYPES; DRUG efficacy; DRUG metabolism
- Publication
Clinical Pharmacology & Therapeutics, 2019, Vol 106, Issue 1, p94
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.1409